Immix Biopharma, Inc.
corporate_fare Company Profile
Immix Biopharma, Inc. (NASDAQ:IMMX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for IMMX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for IMMX spans 8-K, 424B5, 10-Q, FWP.
Recent high-impact activity:
- Immix Biopharma Formalizes $125M Underwritten Offering with J.P. Morgan, Netting $117.1M
- Immix Biopharma Prices $125M Underwritten Offering at $11.00/Share
- Immix Biopharma Reports 89% Complete Response Rate in NEXICART-2, Potential to Reach 98%
- Immix Biopharma Posts 95% CR Rate in NEXICART-2, $232M Cash, and Extended Runway
- $150M Stock Offering Closes for Immix Biopharma, Bolstering Funds After Strong NXC-201 Trial Results
Financial Snapshot
Short Interest & Short Volume
7.75 days to coverFINRA reported short interest of 9,621,660 shares in IMMX as of the September 15, 2026 settlement, a 0.1% increase from the prior period — about 7.8 days to cover at its recent average daily volume. On October 2, 2026, 35.9% of IMMX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IMMX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-29.
Underwritten Offering Priced · Dilution Impact
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →